Daniel Wachtlin

1.7k total citations · 1 hit paper
33 papers, 1.0k citations indexed

About

Daniel Wachtlin is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Pathology and Forensic Medicine. According to data from OpenAlex, Daniel Wachtlin has authored 33 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 7 papers in Physiology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Daniel Wachtlin's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (15 papers), Sarcoidosis and Beryllium Toxicity Research (5 papers) and Systemic Sclerosis and Related Diseases (4 papers). Daniel Wachtlin is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (15 papers), Sarcoidosis and Beryllium Toxicity Research (5 papers) and Systemic Sclerosis and Related Diseases (4 papers). Daniel Wachtlin collaborates with scholars based in Germany, United States and Japan. Daniel Wachtlin's co-authors include Jean‐Baptist du Prel, Bernd Röhrig, T Junginger, Markus Möhler, Heinz Schmidberger, Thomas Borschitz, Maria Blettner, Susanne Stowasser, Luca Richeldi and Maria Blettner and has published in prestigious journals such as New England Journal of Medicine, American Journal of Respiratory and Critical Care Medicine and Annals of the Rheumatic Diseases.

In The Last Decade

Daniel Wachtlin

31 papers receiving 976 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis

2025 28 citations Luca Richeldi, Arata Azuma et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Daniel Wachtlin

Since Specialization

Citations

This map shows the geographic impact of Daniel Wachtlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Wachtlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Wachtlin more than expected).

Fields of papers citing papers by Daniel Wachtlin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Wachtlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Wachtlin. The network helps show where Daniel Wachtlin may publish in the future.

Co-authorship network of co-authors of Daniel Wachtlin

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Wachtlin. A scholar is included among the top collaborators of Daniel Wachtlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Wachtlin. Daniel Wachtlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Initiation of Supplemental Oxygen in the FIBRONEER-IPF Trial of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis 2025 ·American Journal of Respiratory and Critical Care Medicine ·Luca Richeldi, Arata Azuma, Vincent Cottin, Michael Kreuter, Toby M. Maher, (unknown), (unknown), (unknown), Emmanuelle Clerisme-Beaty, (unknown), Daniel Wachtlin, Yi Liu, Christina Schlecker, Susanne Stowasser, Donald F. Zoz, Marlies Wijsenbeek	0
2	Phase III FIBRONEER-IPF Trial of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis 2025 ·American Journal of Respiratory and Critical Care Medicine ·Luca Richeldi, Arata Azuma, Vincent Cottin, Michael Kreuter, Toby M. Maher, (unknown), (unknown), (unknown), Emmanuelle Clerisme-Beaty, (unknown), Daniel Wachtlin, Yi Liu, Christina Schlecker, Susanne Stowasser, Donald F. Zoz, Marlies Wijsenbeek	1
3	Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis breakdown → 2025 ·New England Journal of Medicine ·Luca Richeldi, Arata Azuma, Vincent Cottin, (unknown), Toby M. Maher, Fernando J. Martinez, Justin M. Oldham, Claudia Valenzuela, Emmanuelle Clerisme-Beaty, (unknown), Daniel Wachtlin, Yi Liu, Christina Schlecker, Susanne Stowasser, Donald F. Zoz, Marlies Wijsenbeek	28
4	POS1329 DESIGN OF A PHASE III, RANDOMISED, PLACEBO-CONTROLLED TRIAL OF BI 1015550 IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE 2023 ·Annals of the Rheumatic Diseases ·Toby M. Maher, (unknown), Arata Azuma, Vincent Cottin, (unknown), Michael Kreuter, Justin M. Oldham, Luca Richeldi, Claudia Valenzuela, Marlies Wijsenbeek, Carl Coeck, (unknown), Daniel Wachtlin, Fernando J. Martínez	0
5	Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD) 2023 ·BMJ Open Respiratory Research ·Toby M. Maher, Shervin Assassi, Arata Azuma, Vincent Cottin, Anna‐Maria Hoffmann‐Vold, Michael Kreuter, Justin M. Oldham, Luca Richeldi, Claudia Valenzuela, Marlies Wijsenbeek, Carl Coeck, Christina Schlecker, Florian Voß, Daniel Wachtlin, Fernando J. Martínez	16
6	Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage 2019 ·ERJ Open Research ·Christopher J. Ryerson, Martin Kolb, Luca Richeldi, Joyce Lee, Daniel Wachtlin, Susanne Stowasser, Venerino Poletti	19
7	Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials 2019 ·European Respiratory Journal ·Imre Noth, Marlies Wijsenbeek, Martin Kolb, Francesco Bonella, (unknown), Daniel Wachtlin, Tamera J. Corte	24
8	Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis 2018 ·Respiration ·Michael Kreuter, Ulrich Costabel, Luca Richeldi, Vincent Cottin, Marlies Wijsenbeek, Francesco Bonella, Elisabeth Bendstrup, Toby M. Maher, Daniel Wachtlin, Susanne Stowasser, Martin Kolb	35
9	Continuous intraoperative monitoring of pelvic autonomic nerves during TME to prevent urogenital and anorectal dysfunction in rectal cancer patients (NEUROS): a randomized controlled trial 2016 ·BMC Cancer ·Daniel W. Kauff, Kai Kronfeld, Stanislav Gorbulev, Daniel Wachtlin, Hauke Lang, Werner Kneist	21
10	Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression – The EMC trial 2016 ·European Neuropsychopharmacology ·André Tadić, Daniel Wachtlin, Thomas Berger, Dieter F. Braus, Dietrich van Calker, Norbert Dahmen, Nadine Dreimüller, Alice Engel, Stanislav Gorbulev, Isabella Helmreich, (unknown), Kai Kronfeld, Konrad F. Schlicht, Oliver Tüscher, Stefanie Wagner, Christoph Hiemke, Klaus Lieb	36
11	Rationale and design of the RE-LATED AF—AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus—Effects of Dabigatran in patients with Atrial Fibrillation 2015 ·Clinical Research in Cardiology ·Marion Ferner, Daniel Wachtlin, Torsten Konrad, Oliver Deuster, Thomas Meinertz, Stephan von Bardeleben, Thomas Münzel, (unknown), Günter Breithardt, Thomas Rostock	33
12	A comparison of intervention and conservative treatment for angulated fractures of the distal forearm in children (AFIC): study protocol for a randomized controlled trial 2015 ·Trials ·(unknown), Daniel Wachtlin, Kai Kronfeld, D. W. Sommerfeldt, Lucas M. Wessel	17
13	Neurofeedback in children with attention-deficit/hyperactivity disorder (ADHD) – a controlled multicenter study of a non-pharmacological treatment approach 2014 ·BMC Pediatrics ·Martin Holtmann, (unknown), Daniel Wachtlin, (unknown), Ute Strehl	34
14	Blinded Sample Size Recalculation in Longitudinal Clinical Trials Using Generalized Estimating Equations 2013 ·Therapeutic Innovation & Regulatory Science ·Daniel Wachtlin, Meinhard Kieser	4
15	No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: The ATRACTION study, a phase II randomised trial 2012 ·Digestive and Liver Disease ·Marcus Schuchmann, Jens M. Kittner, JF Schlaak, Dietmar M. Klass, Christoph Eisenbach, Thomas Berg, Christian Trautwein, Rainer Günther, Stefan Zeuzem, (unknown), (unknown), Konrad Neumann, Daniel Wachtlin, Martin F. Sprinzl, Tim Zimmermann, Wulf O. Böcher, Peter R. Galle	2
16	An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer 2011 ·European Journal of Cancer ·Markus Moehler, Annett Mueller, J.T. Hartmann, M. Ebert, Salah‐Eddin Al‐Batran, Peter Reimer, Martin R. Weihrauch, Florian Lordick, Tanja Trarbach, Stefan Biesterfeld, Maria Kabisch, Daniel Wachtlin, Peter R. Galle	73
17	Sample Size Calculation in Clinical Trials 2010 ·Deutsches Ärzteblatt international ·Bernd Röhrig, Jean‐Baptist du Prel, Daniel Wachtlin, Robert Kwiecien, Maria Blettner	92
18	Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder - the EMC trial 2010 ·Trials ·(unknown), André Tadić, Stanislav Gorbulev, Norbert Dahmen, Christoph Hiemke, Dieter F. Braus, J. Röschke, Dietrich van Calker, Daniel Wachtlin, Kai Kronfeld, (unknown), (unknown), Klaus Lieb	23
19	Types of Study in Medical Research 2009 ·Deutsches Ärzteblatt international ·Bernd Röhrig, Jean‐Baptist du Prel, Daniel Wachtlin, Maria Blettner	124
20	Effects of pentaerythritol tetranitrate on endothelial function in coronary artery disease: results of the PENTA study 2009 ·Clinical Research in Cardiology ·Boris Schnorbus, (unknown), Mir Abolfazl Ostad, (unknown), Daniel Wachtlin, Philip Wenzel, Andreas Daiber, Thomas Münzel, Ascan Warnholtz	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact